FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2261017941> ?p ?o ?g. }

• W2261017941 endingPage "e79" @default.
• W2261017941 startingPage "e72" @default.
• W2261017941 abstract "Background Livedoid vasculopathy is a thrombotic skin disease characterised by recurrent occlusion of the cutaneous microcirculation in lower extremities, which results in skin infarctions with painful ulcerations and irreversible scar formation. Rivaroxaban is a direct factor Xa inhibitor that prevents thrombus formation. We investigated whether rivaroxaban is effective for the treatment of livedoid vasculopathy. Methods We did this single-arm, open-label, multicenter, phase 2a, proof-of concept trial at three university hospitals in Germany. Patients with livedoid vasculopathy and a minimum pain score of 40 on the visual analogue scale were eligible to participate. Patients received oral rivaroxaban tablets for 12 weeks at an initial dose of 10 mg twice per day, which was reduced to once per day if a reduction of pain by 50% on the visual analogue scale was achieved. Subcutaneous enoxaparin at 1 mg per kg bodyweight once or twice per day was allowed as a backup treatment in case of insufficient efficacy and increased pain. The primary endpoint was change in pain on the visual analogue scale from baseline to 12 weeks. Efficacy was assessed in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study drug. This trial is registered with the EU Clinical Trials Register, EudraCT number 2012-000108-13-DE, and is closed to new participants. Findings Between Dec 28, 2012, and April 24, 2014, 36 patients were screened, 28 patients were recruited for the study, and 25 patients received treatment. During treatment, five patients dropped out of the study because of withdrawal of consent (one patient), lack of compliance (one patient), violation of inclusion criteria (two patients), and a serious adverse event (one patient). Median pain on the visual analogue scale decreased from 65·0 (IQR 52·0–78·0) at baseline to 6·0 (1·0–14·0) after 12 weeks of treatment (p<0·0001). Six of the 20 patients required additional treatment with enoxaparin. Eight treatment-related adverse events were recorded in six (24%) of the 25 patients: five cases of menorrhagia including one classified as both menorrhagia and dysmenorrhoea, one case of dyspnoea, and one case of gingival bleeding. The only serious adverse reaction to rivaroxaban during the study was one case of menorrhagia in a patient with concomitant endometriosis, which resulted in study discontinuation. Interpretation Rivaroxaban seems to effectively reduce pain in livedoid vasculopathy. Therefore we suggest that rivaroxaban with enoxaparin as a backup treatment is a suitable treatment option for patients with livedoid vasculopathy. Funding Deutsche Forschungsgemeinschaft and Bayer Vital." @default.
• W2261017941 created "2016-06-24" @default.
• W2261017941 creator A5002144514 @default.
• W2261017941 creator A5002605575 @default.
• W2261017941 creator A5034644244 @default.
• W2261017941 creator A5037414415 @default.
• W2261017941 creator A5041563622 @default.
• W2261017941 creator A5044746555 @default.
• W2261017941 creator A5052121217 @default.
• W2261017941 creator A5083044979 @default.
• W2261017941 creator A5086051455 @default.
• W2261017941 date "2016-02-01" @default.
• W2261017941 modified "2023-10-18" @default.
• W2261017941 title "Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial" @default.
• W2261017941 cites W1589446736 @default.
• W2261017941 cites W1591205163 @default.
• W2261017941 cites W1991747552 @default.
• W2261017941 cites W1997251643 @default.
• W2261017941 cites W2008596478 @default.
• W2261017941 cites W2013498060 @default.
• W2261017941 cites W2013750247 @default.
• W2261017941 cites W2019169178 @default.
• W2261017941 cites W2022947323 @default.
• W2261017941 cites W2027200715 @default.
• W2261017941 cites W2033040404 @default.
• W2261017941 cites W203584016 @default.
• W2261017941 cites W2036506340 @default.
• W2261017941 cites W2053201374 @default.
• W2261017941 cites W2073746165 @default.
• W2261017941 cites W2086062220 @default.
• W2261017941 cites W2094750641 @default.
• W2261017941 cites W2095954329 @default.
• W2261017941 cites W2096991001 @default.
• W2261017941 cites W2097854437 @default.
• W2261017941 cites W2101075838 @default.
• W2261017941 cites W2115787552 @default.
• W2261017941 cites W2127668424 @default.
• W2261017941 cites W2129972519 @default.
• W2261017941 cites W2146128628 @default.
• W2261017941 cites W2154875662 @default.
• W2261017941 cites W3191392922 @default.
• W2261017941 cites W4211086828 @default.
• W2261017941 doi "https://doi.org/10.1016/s2352-3026(15)00251-3" @default.
• W2261017941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26853646" @default.
• W2261017941 hasPublicationYear "2016" @default.
• W2261017941 type Work @default.
• W2261017941 sameAs 2261017941 @default.
• W2261017941 citedByCount "57" @default.
• W2261017941 countsByYear W22610179412016 @default.
• W2261017941 countsByYear W22610179412017 @default.
• W2261017941 countsByYear W22610179412018 @default.
• W2261017941 countsByYear W22610179412019 @default.
• W2261017941 countsByYear W22610179412020 @default.
• W2261017941 countsByYear W22610179412021 @default.
• W2261017941 countsByYear W22610179412022 @default.
• W2261017941 countsByYear W22610179412023 @default.
• W2261017941 crossrefType "journal-article" @default.
• W2261017941 hasAuthorship W2261017941A5002144514 @default.
• W2261017941 hasAuthorship W2261017941A5002605575 @default.
• W2261017941 hasAuthorship W2261017941A5034644244 @default.
• W2261017941 hasAuthorship W2261017941A5037414415 @default.
• W2261017941 hasAuthorship W2261017941A5041563622 @default.
• W2261017941 hasAuthorship W2261017941A5044746555 @default.
• W2261017941 hasAuthorship W2261017941A5052121217 @default.
• W2261017941 hasAuthorship W2261017941A5083044979 @default.
• W2261017941 hasAuthorship W2261017941A5086051455 @default.
• W2261017941 hasConcept C126322002 @default.
• W2261017941 hasConcept C127413603 @default.
• W2261017941 hasConcept C141071460 @default.
• W2261017941 hasConcept C14184104 @default.
• W2261017941 hasConcept C203092338 @default.
• W2261017941 hasConcept C2776301958 @default.
• W2261017941 hasConcept C2778661090 @default.
• W2261017941 hasConcept C2779161974 @default.
• W2261017941 hasConcept C2780645631 @default.
• W2261017941 hasConcept C2908647359 @default.
• W2261017941 hasConcept C535046627 @default.
• W2261017941 hasConcept C71924100 @default.
• W2261017941 hasConcept C78519656 @default.
• W2261017941 hasConcept C99454951 @default.
• W2261017941 hasConceptScore W2261017941C126322002 @default.
• W2261017941 hasConceptScore W2261017941C127413603 @default.
• W2261017941 hasConceptScore W2261017941C141071460 @default.
• W2261017941 hasConceptScore W2261017941C14184104 @default.
• W2261017941 hasConceptScore W2261017941C203092338 @default.
• W2261017941 hasConceptScore W2261017941C2776301958 @default.
• W2261017941 hasConceptScore W2261017941C2778661090 @default.
• W2261017941 hasConceptScore W2261017941C2779161974 @default.
• W2261017941 hasConceptScore W2261017941C2780645631 @default.
• W2261017941 hasConceptScore W2261017941C2908647359 @default.
• W2261017941 hasConceptScore W2261017941C535046627 @default.
• W2261017941 hasConceptScore W2261017941C71924100 @default.
• W2261017941 hasConceptScore W2261017941C78519656 @default.
• W2261017941 hasConceptScore W2261017941C99454951 @default.
• W2261017941 hasIssue "2" @default.
• W2261017941 hasLocation W22610179411 @default.
• W2261017941 hasLocation W22610179412 @default.
• W2261017941 hasOpenAccess W2261017941 @default.

• next